Back to Search
Start Over
Insulin-derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases.
- Source :
-
Journal of diabetes investigation [J Diabetes Investig] 2020 Jul; Vol. 11 (4), pp. 1002-1005. Date of Electronic Publication: 2020 Jan 19. - Publication Year :
- 2020
-
Abstract
- To date, almost all case reports of insulin-derived amyloidosis described the presence of a subcutaneous mass that was observable on physical examination. This report presents two cases of insulin-derived amyloidosis without palpable masses at insulin injection sites. In both cases, blood glucose concentrations improved, and the insulin dose could be reduced by an average of 45% after changing the insulin injection sites. The insulin absorption at the site was reduced to at most 40% of that at a normal site in one case. Magnetic resonance imaging and ultrasonography were useful to screen and differentiate insulin-derived amyloidosis without a palpable mass. This report showed that insulin-derived amyloidosis without a palpable mass can be present at the insulin injection site, and has similar clinical effects to insulin-derived amyloidosis with palpable masses.<br /> (© 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)
- Subjects :
- Abdomen pathology
Aged, 80 and over
Amyloidosis chemically induced
Humans
Hypoglycemic Agents administration & dosage
Insulins administration & dosage
Male
Amyloidosis pathology
Diabetes Mellitus, Type 2 drug therapy
Hypoglycemic Agents adverse effects
Injections, Subcutaneous adverse effects
Insulins adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 2040-1124
- Volume :
- 11
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Journal of diabetes investigation
- Publication Type :
- Report
- Accession number :
- 31867887
- Full Text :
- https://doi.org/10.1111/jdi.13199